ATRC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ATRC is not a good immediate buy for a Beginner with a long-term focus and $50,000-$100,000 to deploy. The business is growing and the analyst backdrop is still broadly positive, but the current setup lacks a strong technical entry and the options/proprietary signals do not support an aggressive buy right now. My direct view: hold off for a better entry rather than buying today.
ATRC closed at 27.6, slightly below the prior close of 27.8, with the regular session down 0.75%. The stock is trading below the pivot at 28.303 and only modestly above support at 27.102, which suggests it is still range-bound rather than in a confirmed uptrend. MACD histogram is positive but contracting, RSI_6 at 40.57 is neutral-to-weak, and moving averages are converging. This points to a mixed short-term trend with no strong bullish momentum. The nearby support/resistance structure favors caution until price reclaims the pivot and shows follow-through above 29.5.
Congress trading data is also modestly supportive, with 1 purchase and no sales over the last 90 days.
Net income was only $108K and EPS was $0, showing profitability is still thin despite revenue growth. The stock faces competitive overhangs from Edwards Lifesciences and prior Medtronic pressure, which have already led to multiple target cuts and one downgrade to Perform/Neutral. The current technical setup is not strongly bullish, and the stock trend model suggests downside risk over the next day and week. Insider and hedge fund trading trends are neutral.
Latest quarter: Q1 2026. Revenue increased to $141.249M, up 14.26% YoY, which is a healthy growth trend. Gross margin improved to 77.39%, up 3.28 points YoY, indicating stronger unit economics. However, net income fell to $108K and EPS dropped to 0, so bottom-line profitability remains limited despite the stronger sales growth. Overall, the quarter was good on growth and margins, but not yet compelling on earnings power.
Recent analyst sentiment remains mostly positive but more cautious than before. Canaccord raised its target to $55 and kept Buy, UBS kept Buy with $55, Citizens kept Outperform with $52, and Freedom Capital initiated Buy at $43. Offsetting this, JPMorgan downgraded to Neutral with a $36 target and Oppenheimer downgraded to Perform. The street’s pros view: durable growth, margin expansion, and a resilient clinical/competitive moat. The cons view: increasing competition from Edwards and valuation/competition pressure that could limit upside. Net-net, analysts are still constructive, but the mix has become more divided.
